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The progress of PD and its related disorders cannot be prevented with the medications available. In this study, we recruited 8 PD
and 4 PD plus patients between 5 to 15 years after diagnosis. All patients received BM-MSCs bilaterally into the SVZ and were
followed up for 12 months. PD patients after therapy reported a mean improvement of 17.92% during “on” and 31.21% during
“oﬀ” period on the UPDRS scoring system. None of the patients increased their medication during the follow-up period. Sub-
jectively, the patients reported clarity in speech, reduction in tremors, rigidity, and freezing attacks. The results correlated with the
duration of the disease. Those patients transplanted in the early stages of the disease (less than 5 years) showed more improvement
and no further disease progression than the later stages (11–15 years). However, the PD plus patients did not show any change in
their clinical status after stem cell transplantation. This study demonstrates the safety of adult allogenic human BM-MSCs trans-
planted into the SVZ of the brain and its eﬃcacy in early-stage PD patients.
1.Introduction
Shaking Palsy (Paralysis Agitans) or Parkinson’s disease (PD)
was originally described by James Parkinson in 1817 as
“Involuntary tremulous motion, with lessened muscular
power, in parts not in action and even when supported; with
a propensity to bend the trunk forwards, and to pass from
a walking to a running pace: the senses and intellects being
uninjured” [1].
Ever since the ﬁrst description, scientists have pursued
the causes and treatment of the disease. It is a chronic neu-
rodegenerative disorder due to selective loss of dopaminergic
neurons in the Substantia Nigra (SN) and the presence of
proteinaceous inclusions known as Lewy bodies [2]. PD is
recognizedasone ofthemost commonneurologic disorders,
aﬀecting approximately 15% of individuals older than 60
years.Betweentheagesof75and84,thatpercentagemayrise
to almost 30%.
The causes of idiopathic Parkinson-disease (IPD) are be-
lieved to be a combination of genetic and environmental fac-
tors. Recent studies indicate that the pathogenesis includes a
cascadeofmolecularandcellularevents,oxidativestress,and
release of reactive oxygen species (ROS), apoptosis, dysfunc-
tioningofmitochondriaandoftheproteindegradingsystem.
Even immune-mediated mechanisms are being suggested for
the progression and to explain the drug resistance that hap-
pens with time [2, 3].
The cardinal symptoms for PD are bradykinesia, rigidity,
tremor, and instability which can be treated with dopamine
replacement drugs. However, these drugs are unable to inter-
rupt the progress of the disease and are ineﬀective against the
disabling gait freezing, postural instability, lethargy, and lack
of facial expressions. Also, over time there are drug-induced
motor system complications; hence, it is suggested to delay
the therapy till it signiﬁcantly limits the patient’s activities of
daily living [4].2 Stem Cells International
It is an established fact that much earlier to the clinical
manifestations of the disease there are functional and struc-
tural changes in the nigrostriatal pathways which leads to
a fall in the dopamine levels; releasing its inhibition and
increasing the excitatory activities of the subthalamic nuclei
andcorticostriatalconnections[1,5].Compensatorymecha-
nisms are capable of maintaining the balanced neuronal out-
put but not for long. Therefore, it was essential to search for
alternate options to improve neuronal activity in the degene-
ratedpartofthebrain.Thisleadtocellreplacementtherapies
being identiﬁed as the most suitable option for PD as there is
selectivelossofdopaminergicneuronsinthesubstantianigra
[6–10].
Over the years, numerous sources of dopamine-secreting
cells like fetal mesencephalic tissue, human embryonic stem
cells, and neural stem cells have been investigated with
varying degrees of eﬃciency [6–8]. Although fetal mesen-
cephalic tissue and embryonic stem cells showed a lot of pro-
mise, they are limited by the availability of fetal tissue and
ethicalconcerns,persuadingscientiststolookdeeperintothe
problem. This led to challenge the decade old hypothesis that
regeneration is not possible in the brain. Stem cells were dis-
coveredinspeciﬁcsitesintheCNSsuchasthesubventricular
zone-SVZ(aroundthelateralventricles)andtheirpropensity
to migrate to the traumatized areas of the nervous system.
Numerous studies also conﬁrm the diﬀerentiation capacity
of stem cells into dopaminergic neurons in the presence of
v a r i o u se x t e r n a lc u e s[ 11–13].
As a result, stem cells have emerged as a promising area
helpful for tissue regeneration. Bone marrow mesenchymal
stem cells (BM-MSCs) have the potential to diﬀerentiate into
diﬀerent lineages including functional dopaminergic neu-
rons[14]withoutformingtumours.Animalstudiesillustrate
that these cells have the property to migrate/home to the
lesioned region as they respond to the chemoattractants
released at the site [15–18].
An earlier report by our group in 2010 established the
immediate and short-term safety of autologous bone-mar-
row derived mesenchymal stem cells in the transplantation
therapy of PD and traumatic spinal cord injury patients [19].
Although the clinical improvement was only marginal, most
of the patients experienced subjective well being without any
notablesideeﬀects.Symptomslikefreezingandfacialexpres-
sionsshowedatendencytowardsimprovement.However,we
noticedavariationintheBM-MSCswhichwereattributedto
age and probably to long-standing disease. This encouraged
ustocarryoutfurtherstudiesinPDusingBM-MSCstoover-
come the variable in the previous study.
2.MaterialsandMethods
A clinical study was designed to determine the safety, feasi-
bility, and eﬃcacy of allogenic adult bone-marrow-derived
mesenchymal stem cells in Parkinson’s disease (PD) patients.
According to the national guidelines, Institutional Ethics
Committee (IEC) approval was obtained for conducting the
study.Necessaryapprovalsforisolation,culturing,andtrans-
plantation of stem cells were also taken. Each patient who
participated in the study was counseled on the procedure
andinformedconsentobtained.Thepatientwasscreenedfor
HIV, HBV, HCV, CMV, and VDRL by a nationally certiﬁed
testing laboratory before being included in the study. All
deviationstotheprotocol,dropouts,andadverseeventswere
documented and informed to the IEC.
2.1. Study Design and Randomization. The study was con-
ducted as a prospective, uncontrolled, one year, single centre
safety, and eﬃcacy clinical study of allogenic BM-MSCs bi-
laterally transplanted in patients diagnosed with PD.
2.2. Isolation of Mesenchymal Stem Cells from Healthy Adult
Donors
2.2.1. Selection of Healthy Donors. Healthy donors were
selected according to the donor inclusion criteria and as per
theguidelineofInternationalSocietyofCellTherapy(ISCT).
Healthy donors were either male or female in the age group
of18–30 yearsofage,abletounderstandthevoluntary dona-
tion program, and ready to provide voluntary written infor-
med consent. Donors were excluded if they have illness such
as autoimmune disorders, tuberculosis, malaria and any
otherinfection,anyillnesswhichprecludestheuseofgeneral
anesthesia, history of malignancy, diabetes, hypertension,
signiﬁcant heart disease, genetic or chromosomal disorders,
history of any inherited disorders, hemoglobin less than 10,
and pregnant women.
At the time of obtaining informed consent they were
screened for infection with human immunodeﬁciency virus
(HIV), hepatitis B (HBV), hepatitis C (HCV), cytomegalo-
virus (CMV), and syphilis (VDRL) using reverse trans-
criptase-polymerase chain reaction (RT-PCR) method and
excludediffoundpositive.Theywerealsotestedforcomplete
blood count (CBC), renal function test (RFT), liver function
tests(LFT),bloodglucose,chestX-ray,Echocardiogram,and
Electrocardiogram (ECG).
2.2.2. Isolation of Mesenchymal Stem Cells. BM-MSCs were
isolatedfromhealthyscreeneddonorsbetweentheageof18–
30 years with informed consent. 60 milliliter of bone marrow
was aspirated aseptically under local anesthesia from iliac
crestofthehealthyscreeneddonors.Thesamplewillbetran-
sported appropriately to the processing lab consisting of a
class 1000cGMP facility, and all sample processing was done
in a class 100 biosafety cabinet. Bony spicules and particles
were removed using a cell strainer and further diluted with
DMEM-KO, centrifuged at 1800rpm for 10 minutes at 20◦C.
The cells were resuspended with DMEM-KO and gently
layered onto a density gradient solution (Lymphoprep, Axis
Shield PoC AS, Oslo, Norway) to obtain an enriched mono-
nuclear fraction. This was washed with DMEM-KO and cen-
trifuged to collect the cells. The cells obtained were resus-
pended and plated in MSC complete culture medium con-
sisting of Dulbecco’s modiﬁed Eagle Medium (DMEM-KO)
10% fetal bovine serum (FBS) from preselected lots, and glu-
taMAX as described elsewhere [20]. The culture was main-
tained at 37◦C in a humidiﬁed atmosphere containing 95%
air and 5% CO2 and subcultured prior to conﬂuency.Stem Cells International 3
2.3. Subculturing and Expansion. Once 80% conﬂuent these
cells were dissociated with 0.25% trypsin/0.53mM EDTA
(Invitrogen) and further upscaled and expanded in order to
provide the required number of cells to the patient. Brieﬂy,
trypsinized cells were reseeded at a density of 1000cells per
cm2 incellstacks(Corning).After14daysinculture,thecells
reached 80% conﬂuency and were ready for transplantation.
2.4. Quality Control Testing. MSCs were tested for quality
control parameters such as Mycoplasma, Endotoxin, sterility
and cell surface markers such as CD73, CD90, CD105,
CD166, CD34, and CD45 markers using ﬂow cytometry.
They should be more than 80% positive for CD73, CD90,
CD166, and CD105 but negative [<10%] for CD34 and
CD45.
2.5. Characterization of Mesenchymal Stem Cells
2.5.1. Immunophenotype. Immunophenotyping of the cul-
turedBMMSCwasperformedusingﬂowcytometrytoiden-
tify the presence of speciﬁc cell-surface antigens. Brieﬂy, BM
MSCs were dissociated with 0.25% trypsin-EDTA and resus-
pended in wash buﬀer at a concentration of 1 × 10cells/mL.
Cellviabilitywasmeasuredbyﬂowcytometryusing7-amino
actinomycin D (7-AAD) 200μL cell suspension were incu-
bated in the dark for 30min at 4◦C with saturating concen-
trations of phycoerythrin PE-conjugated antibodies. Appro-
priate isotype-matched controls were used to set the instru-
ment parameters. After incubation, cells were washed three
t i m e sw i t hw a s hb u ﬀer and resuspended in 0.5mL wash
buﬀer for analysis. Flow cytometry was performed on a 5HT
Guava instrument. Cells were identiﬁed by light scatter for
10000 gated events and analyzed. The following markers
were analyzed: CD34-PE, CD45-PE, CD73-PE, CD105-PE,
CD166-PE, and CD90-PE (BD Pharmingen, San Diego, CA,
USA).
2.5.2. Diﬀerentiation. The trilineage diﬀerentiation capacity
of human BM MSC into osteoblasts, adipo cytes and chon-
drocytes was investigated to conﬁrm mesenchymal proper-
ties. Brieﬂy osteoblast diﬀerentiation was induced by cultur-
ing human BM MSC in Stempro Osteogenesis Diﬀerentia-
tion kit (Life Technologies, USA) for 15 days as per the rec-
ommendations provided by the manufacturers. Fresh med-
ium was replenished every 3 days. Calcium accumulation
was assessed by Von Kossa staining. The diﬀerentiated cells
were washed with DP BS and ﬁxed with 10% formalin for
30min. The ﬁxed cells were incubated with 5% silver nitrate
for60minunderultraviolet(UV)lightandthentreatedwith
2.5% sodium thiosulphate for 5min. Images were captured
using an Nikon Eclipse 80i microscope (Nikon Corporation,
Towa Optics, New Delhi, India).
To induce adipogenic diﬀerentiation, human BM MSC
were cultured for 21 days using Adipogenesis diﬀerentiation
kit (Life Technologies, USA) as per the protocol recom-
mended by the manufacturers. Medium was replenished
every3days.Cellswereﬁxedin10%formalinfor20min,and
200μL Oil Red O staining solution was added and incubated
for 10min at room temperature. The cells were rinsed ﬁve
times with distilled water. The images were captured using
a Nikon Eclipse 80i microscope (Nikon Corporation, Towa
Optics, New Delhi, India). For chondrogenic diﬀerentiation,
human BM MSC were cultured for 21 days using chondroge-
nesis diﬀerentiation kit (Life Technologies, USA) as per the
manufacturer’s recommendations and stained with Safranin
Oasspeciﬁed.TheimageswerecapturedusingNikonEclipse
80i microscope (Nikon Corporation, Towa Optics, New
Delhi, India).
2.5.3. Karyotyping. To rule out any chromosomal aberra-
tions during in vitro propagation of BM MSC, these cells
were karyotyped prior to transplantation. The chromosomes
were visualized using a standard G-banding procedure, and
more than 200cells were analyzed per sample and reported
according to the International System for Human Cytoge-
netic Nomenclature (ISCN).
2.6. In Process Test. Prior to dispatching the cells for trans-
plantation, a battery of in-process quality testing was perfor-
med on the cells. These include morphology, immunophe-
notyping cell surface marker analysis, endotoxin testing
using LAL test, and mycoplasma using RT-PCR was also
done. Only those cells fulﬁlling the ISCT criteria for MSCs
were released for transplantation.
Any sample positive for endotoxin and mycoplasma was
discarded immediately and appropriately.
2.7. End Product Test. The ﬁnal cell suspension which was
provided to the clinician for transplantation was again tested
for cell surface marker analysis as mentioned above. In ad-
dition, karyotyping, endotoxin, and mycoplasma were also
performed as mandatory quality testing. Cell viability was
measured by ﬂow cytometry using 7AAD (7-amino actino-
mycin D). Certiﬁcate of analysis (COA) was prepared, and
cells were released along with documentation for transplan-
tation.
2.8. Patient Selection. Subjects, both male and female bet-
ween 18–80 years, were enrolled for this study. The patients
were screened for HIV, HBV, HCV, CMV, and VDRL fol-
lowed by inclusion criteria selection before participating in
thetrial.8PDpatientsand4PDplussyndromepatientswere
chosen for the trial (those patients diagnosed with multiple
system atropy and progressive supranuclear palsy (PSP) have
been classiﬁed under PD plus syndrome patients). This
would help us understand the role of bone-marrow-derived
mesenchymal stem cells in the early stages of the disease and
in rapidly progressing PD plus syndrome patients.
Those patients who fulﬁlled the following inclusion and
exclusion criteria were included for the study.
Inclusion Criteria
(1) Should be in the age group of 18–80 years.
(2) Should be fully conscious, alert, and oriented while
providing consent.
(3) Should show signiﬁcant motor and nonmotor symp-
toms.4 Stem Cells International
(4) Subject should provide a written informed consent
and agree to return for follow up.
(5) SubjectshouldbeclinicallydiagnosedforParkinson’s
disease and PD included disorders with motor com-
plications despite adequate oral anti-Parkinsonian
therapy.
(6) Should be able to comply with and understand the
required visit schedule.
Exclusion Criteria
(1) Patient is suﬀering from Dementia (MMSE < 25).
(2) The extent or severity of the disease is not measur-
able.
(3) If the subject suﬀers form preexisting medical condi-
tions such as bleeding disorders, and septicemia.
(4) Patients with a past (within one year) or present his-
tory of psychiatric disorder.
(5) If the subject has been enrolled in other investiga-
tional drug trial or has completed any trial within the
last 3 months.
(6) If hemoglobin < 10gm/dL, serum creatinine <
2mg/dL, serum total bilirubin < 2mg/dL, and
HbA1c < 7%.
(7) Pregnant or nursing or women in child bearing age
without adequate contraception.
(8) ThesubjecttestedpositiveforHIV,HCV,HBV,CMV,
or VDRL.
2.9. Clinical Evaluation. These patients were admitted 48
hours prior to the procedure, and a detailed clinical eval-
uation was performed including UPDRS, MMSE, gait and
neuropsychological assessments. General physical examina-
tion and cardiac status of the patients were evaluated before
inclusion into the study. MRI was done at the baseline and at
12monthfollowup. MRTractographywasconductedat3rd,
6th and 9th month follow up sessions.
2.10.MRIImagingandTractography. MRIimagingwasdone
on a 1.5 5T (Wipro GE, Milwaukee, WI, USA) machine.
Routine imaging was done with axial FLAIR and T2W
images and Sagittal T1W images. DTI of brain was done in
the axial plane using an 8-channel CTL array spine coil with
the following parameters-25 directions EPI tensor imaging
(TR 8500, TE: 97.6 b value: 1000 frequency: 128, phase 128,
NEX-1, slice thickness: 5mm with zero interslice gap and
bandwidth: 250kHZ).
2.11. Image Processing. Image processing was done using
FuncTool software provided by GE and quantitative analysis
was done to calculate fractional anisotropy using standard
methods. ROI were placed in bilateral centrum semiovale,
genu, splenium of corpus callosum, anterior limb of internal
capsule, posterior limb of internal capsule, and cerebral ped-
uncles (total of 12 ROI).
2.12. Statistical Analysis. Descriptive statistical analysis has
been carried out in the present study. Results on continuous
measurements are presented on Mean ± SD (min-max) and
resultsoncategoricalmeasurementsarepresentedinnumber
(%). Signiﬁcance is assessed at 5% level of signiﬁcance. Stu-
dent t-test (two tailed, dependent) has been used to ﬁnd the
signiﬁcance of study parameters on continuous scale within
each group.
2.13. Processing of Cells for Intracranial (IC) Transplantation.
As mentioned in the earlier study [19] the cells were pro-
cessed for transplantation. Brieﬂy, after harvesting step, the
total cell count was taken using a standard hemocytometer.
The cells were washed several times with normal saline solu-
tion. Finally the cells were resuspended in saline containing
0.2% human serum albumin. The cell suspension (2mL)
was equally distributed into two 2mL syringes and labeled.
These were packaged in a sterile container and dispatched in
atransportationcontainermaintainedat22◦Ctothehospital
for transplantation via the shortest route.
2.14. Surgical Procedure. The patient was positioned supine
for the transplantation and the parts aseptically prepared.
Under short propofol anesthesia bilateral frontal burr holes
were drilled and small dural openings made. The sub ven-
tricular zone was accessed through a standard brain cannula
with CRW stereotactic frame or Stealth (Medtronic) navi-
gation assistance. BM-MSCs, at a dose of 2 million cells/kg
body weight, were transplanted into the brain and gelfoam
placed over the dural defect prior to closing of the wound.
After operation the patients were observed in the neu-
rointensive care unit for 24 hours following which they were
shifted to the ward and discharged home on the 4th/5th day.
2.15. Evaluations and Follow-Up Schedule. The patients were
followed up closely every three months for one year. They
wereassessedbyanindependentneurophysicianandamove-
ment disorders specialist. During each visit the patient was
clinically examined, UPDRS score performed, neurologically
assessed, and medications reviewed. At the ﬁnal follow-up
visit, that is, 12th month the patient would undergo a MRI
scan to check for any structural changes in comparison to
the baseline scan. The medication would be reviewed at each
visit and adjusted based on the symptoms. Any adverse event
would be reported to the concerned investigator and IEC.
3. Result
In this study, 12 patients were recruited according to the
study design as per the inclusion and exclusion criteria
mentioned above. This included 9 males and 3 females in the
age group of 37–69 years. The duration of the disease varied
between 3 and 15 years in the study group. Out of the 12 pa-
tients,4werediagnosed asPDplusandbelongedtotheolder
agegroup.Thedetailsofthepatientswhoparticipatedinthis
study are mentioned in Table 1.
2 million cells/kg body weight suspended in 2mL of
saline was implanted bilaterally into the subventricular zoneStem Cells International 5
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Figure 1: Characterization of adult BM-MSCs prior to transplantation as per ISCT criteria. It shows the plastic adhered spindle-shaped
ﬁbroblast like appearance of adult BM-MSCs in culture (lower left panel). And the surface expression of CD markers (top panel: negative
markers and lower panel: positive markers).
using burr hole surgery technique. All patients tolerated the
procedure well, there were no postoperative complications
and were discharged within a week’s time from the hospital.
This indicates that there were no immediate cytotoxic eﬀects
due to implantation of allogenic bone marrow mesenchymal
stem cells in to the sub-ventricular zone of the brain and the
procedure was safe.
3.1. Allogenic BM-MSCs. 3 adult healthy screened donors
were recruited for the aspiration of bone marrow under
general anesthesia. BM-MSCs were isolated and cultured as
described in [20]. These cells were cryopreserved and appro-
priately propagated once the patients were recruited for the
study. All the cells were assessed for their morphology, im-
munophenotype and diﬀerential potential.
3.2. Characterization of BM-MSCs
3.2.1. Morphology and Immunophenotype. The cells dis-
played a typical spindle shaped ﬁbroblast-like appearance as
showninFigure 1andﬂowcytometricanalysisshowsthecell
surface expression of CD markers (as per ISCT) as shown in
Figure 1.T h ec e l l sw e r ef o u n dt ob eC D 3 4 −/CD45−/CD73+/
CD90+/CD105+/CD166+ as depicted in Figure 1.
3.2.2. Multipotent Characteristics. In order to ensure that the
BM-mesenchymal stem cells maintain their typical proper-
ties, the trilineage diﬀerentiation capacity of these cells was
demonstrated. The cells were found to undergo adipogenic,
osteogenic and chondrogenic diﬀerentiation as determined
by Oil Red O stain, Von Kossa stain and Safranin O stains,
respectively,(Supplementarydata(Figure 2)willbeavailable
online at doi: 10.1155/2012/931902).
This set of analysis conﬁrms that the cells being used for
the clinical study are truly mesenchymal in nature.
3.2.3. Karyotype. All the samples used for transplantation
were processed for karyotyping prior to transplantation by
a trained cytogeneticist. No abnormalities/aberrations were
noted after ex vivo propagation. A representative ideogram is
shown in the Supplementary data (Figure 3).
3.3. Clinical Assessment. Clinical assessment was performed
on all patients based on 4 basic parameters of the UPDRS
scoring system: (1) mental behavior and mood, (2) activities
ofdailyliving,(3)motordisabilitiesandimpairment,and(4)
complications of PD therapy. This was considered as the pri-
mary measurable outcome of the clinical study. The scoring
was typically done during the “oﬀ” period (approx.12 hours
oﬀ the anti-Parkinsonian medication) and during the “on”
period (within 1-2hrs of the medication) where maximum
beneﬁt could be appreciated in the PD symptoms. The
average score during the “on period” at baseline was 62.33
and after stem cell transplantation it improved to 51.16 that
is, an improvement of 17.92% over the baseline (Figure 2).
Similarly for the “oﬀ period”, the average score was 86.5
at baseline and reduced to 59.5 after 12 months of stem
cell transplantation. The percentage improvement in the “oﬀ
period” score was 31.21% (Figure 3). This is similar to the
data reported earlier by our group using autologous bone-
marrow-derived mesenchymal stem cells [19].
Most of the PD patients reported subjective improve-
ment during the ﬁrst follow up that is, at 3 months after stem
cell transplantation. These include clarity in speech, reduced
tremors, and rigidity, and general sense of well being. These
changes were seen in the later follow ups too indicating that
the changes were not transient but more permanent. Similar
improvements were also noted for some of PD plus patients
but not all. However, for these patients the changes were
transient and by the next follow up (6th month) most of
them had progressed further into the disease.
3.4. Improvement in Relation to the Duration of the Disease.
As depicted in Figure 5 and Table 2, there is a direct
correlation observed between the duration of the disease
and the improvements noted in the PD patients. Patients
who had been diagnosed more recently performed better
on the UPDRS compared to ones with the long-standingStem Cells International 7
Table 2: Shows the improvement in UPDRS scores for PD patients
before and after stem cell transplantation.
Duration of PD Percent of change in UPDRS scores
(in yrs) OFF period ON period
5 34.17 6
5 70.21 62.06
5 56.81 68.42
10 14.28 5.55
11 6.9 12.5
15 16.12 1
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Figure 2: Shows the mean ± SD of the UPDRS score of the PD pa-
tients during “OFF” and “ON” periods at baseline and after stem
cell transplantation. The scores have been assessed during the
screeningvisitandﬁnalvisit12monthsaftertransplantation. ∗Rep-
resents the level of signiﬁcance.
illness. Table 2 shows that those patients with PD for less
than 5 years improved much quicker and remained in stable
comparison to the patients suﬀering for more than 10–15
years. Whereas PD plus patients did not show improvement
or such correlation after transplantation. Though there had
been a subjective initial improvement, it never sustained in
the long-term for PD plus syndromes.
It needs to be mentioned that the PD plus patients could
not be rated using the UPDRS scoring system after stem cell
transplantation due to the severity and progression of the
disease. Hence, this data has not been mentioned.
MRI Studies. MRI of the brain was done before and 12
months after stem cell therapy as shown in Figure 4.T h e
brain images showed similar changes before and after treat-
ment. No signiﬁcant diﬀerences could be appreciated in the
images. There were no structural changes, leukomalacia, or
any additional growth observed. In one patient, incidental
asymptomatic lacunar infarct was seen on follow up.
MR Tractography. The results of MR tractography have been
shown in Tables 3(a) and 3(b). 12 diﬀerent sites of the brain
were analyzed during the diﬀerent stages of follow up. A
trend of improvement was observed in the genu and the ped-
uncles steadily over a period of 12 months. The values
100
120
140
80
60
40
20
0
55 5 1 0 1 1 1 5
U
P
D
R
S
 
s
c
o
r
e
Duration of symptoms vs % improvement in UPDRS 
       score for PD patients post stem cell therapy
Duration of PD symptoms (years)
UPDRS % change in scores at the ON period
UPDRS % change in scores at the OFF period
Figure 3: Illustrates the improvement in UPDRS scores for PD pa-
tients before and after stem cell transplantation. The graph high-
lights the fact that the patients treated early at the onset of the dis-
ease (5 years) have shown signiﬁcantly better improvement which
correlates clinically. The patients that were treated between 10–15
years after the diagnosis of PD did not show any signiﬁcant impro-
vement.
improvedfrom0.53±0.13to0.69±0.07intherightgenuand
0.54 ± 0.14 to 0.63 ± 0.14 in the left genu and 0.50 ± 0.14
to 0.64 ± 0.04 in the left peduncle with a signiﬁcant impro-
vement on the 2nd follow up in the right peduncle. Interest-
ingly in the PD plus patients, there was a further reduction
in the values even after stem cell transplantation. It reduced
from 0.378 ± 0.1255 to 0.3555 ± 0.1219 in the right genu
and from 0.3875 ± 0.0723 to 0.3515 ± 0.1135 in the anterior
limb of the internal capsule. 2 out of 4 patients have shown
no improvement in FA values (i.e., FA values are decreasing
in both the limbs of internal capsules on follow up scans).
This correlated clinically with further deterioration of the
symptoms in the PD plus syndromes.
3.5. Dose of Medication. The dosage of anti-Parkinsonism
medication before and after stem cell transplantation was
analyzed. For 4 PD plus patients, the clinician recommended
an increase in dosage of medication based on their progres-
sion of the disease. However, for the PD patients in the arly
stages of the disease similar increase in dosage was not requi-
red. The dosage has remained the same as the baseline med-
ications prescribed. This indicates that the disease has not
progressed further after stem cell transplantation. Only for
2 patients, the dosage of Syndopa had to be increased. This
is probably because the disease had already advanced beyond
repair at the time of stem cell transplantation which is also
evident from the UPDRS scores of the patients.
Therefore, out of the 8 PD patients, intervention was in
the early stages in 6 patients. The progression of the disease
appears to have been slowed after the administration of stem
cells. They did not require enhancement of dose. In the late
stages of disease and PD plus patients, stem cell transplan-
tation had shown relatively lesser symptomatic relief and on
the other hand needed an increase in medications.8 Stem Cells International
(a)
(b)
Figure 4: Shows T2 FLAIR axial images. (a) Depicts bilateral asymmetric multifocal hyperintensities involving pontine base periventricular
and deep white matter suggestive of small-vessel ischemia. Diﬀuse brain atrophy is also seen with mineralization below globus pallidus and
substantia nigra indicative of PD. There is no signiﬁcant diﬀerence noted between the baseline and follow-up MRI. (b) Depicts moderate
brain atrophy with bilateral putaminal rim sign seen. Small-vessel ischemic changes are seen in the bilateral periventricular and deep white
matter. Mineralization of bilateral lentiform nuclei, dentate nuclei, and substantia nigra visualized is suggestive of MSA-P or PD plus synd-
rome. There was no signiﬁcant diﬀerence noted between the baseline and follow-up MRI.
3.6. Activities of Daily Living. Care givers have noticed an
overall improvement in their activity levels in 7 patients,
which includes reduction in tremors both at rest and in
motion, better clarity in speech, reduction in rigidity, ability
to walk for longer distances and perform personal tasks in-
dependently. This has a signiﬁcant impact on the well being
ofthepatientandfurthersubstantiatesthefactthattheprog-
ression of the disease has been slowed down after stem cell
therapy.
4. Discussion
The current treatment for PD includes pharmacotherapies
and deep brain stimulation techniques. Lesioning surgery is
gradually fading. However, these can only produce symp-
tomatic relief and have their own limitations and long-term
side eﬀects. Therefore, the need for alternative therapy is the
need of the hour. Fetal nigral striatal grafts and neural stem
cells are successful candidates used in the last few decades
as a choice for PD. However, due to the fetal source it has
ethical, immunological, tumorigenic risks besides sourcing
concerns [8]. This has led scientists to explore further into
the capacity of adult stem cells as a therapeutic target for
PD since these are proven to be relatively safe, free of ethical
issues, do not form tumours and have immunomodulatory
potential.Studieshaveprovedthatbothembryonicandadult
stem cells in vitro can be transdiﬀerentiated into functional
dopamine secreting cells [14, 21, 22]. Animal data suggests
that it is possible to transplant these cells into the brain and
have therapeutic beneﬁts in PD [23–25]. Hence, in this study
we have chosen adult bone-marrow-derived mesenchymal
stem cells.
In our ﬁrst study [19], we have demonstrated the safety
ofautologousbone-marrow-derivedmesenchymalstemcells
transplanted unilaterally into the SVZ. However, with mixed
results. Some patients showed improvement. There was an
initial improvement period followed by a deterioration of
the symptoms. This was possibly due to the continued dege-
neration in the nongrafted side. To nullify this eﬀect, in the
current study, we have undertaken bilateral stem cell trans-
plantation.
During the earlier study we also noted that there is a
diﬀerence in the population doubling time (PDT), morphol-
ogy, diﬀerential potential, and cell senescence. Although theStem Cells International 9
Table 3: MR tractography: (a) Average ± SD of Levels of fractional anisotropic values (FA) in 12 diﬀerent sites in brain of PD patients. (b)
Average ± SD of Levels of fractional anisotropic values (FA) in 12 diﬀerent sites in brain of PD plus patients.
(a)
Site
FA values
Baseline 1st follow up 2nd follow up 3rd follow up
CSO-right 0.48 ± 0.09 0.46 ± 0.07 0.48 ± 0.15 0.50 ± 0.02
CSO-left 0.48 ± 0.07 0.48 ± 0.10 0.47 ± 0.11 0.51 ± 0.13
AL-right 0.42 ± 0.08 0.42 ± 0.09 0.36 ± 0.05 0.48 ± 0.19
AL-left 0.40 ± 0.07 0.36 ± 0.06 0.38 ± 0.08 0.33 ± 0.04
PL-right 0.66 ± 0.06 0.57 ± 0.14 0.64 ± 0.09 0.61 ± 0.16
PL-left 0.65 ± 0.11 0.60 ± 0.12 0.65 ± 0.07 0.61 ± 0.24
Genu-right 0.53 ± 0.13 0.56 ± 0.11 0.50 ± 0.16 0.69 ± 0.07
Genu-left 0.54 ± 0.14 0.58 ± 0.07 0.51 ± 0.11 0.63 ± 0.14
SPL-right 0.67 ± 0.12 0.69 ± 0.06 0.66 ± 0.11 0.65 ± 0.08
SPL-left 0.65 ± 0.19 0.73 ± 0.03 0.69 ± 0.10 0.59 ± 0.27
Peduncles-right 0.52 ± 0.13 0.53 ± 0.07 0.61 ± 0.08 0.56 ± 0.08
Peduncles-left 0.50 ± 0.14 0.56 ± 0.08 0.55 ± 0.05 0.64 ± 0.04
(b)
Site Baseline Follow up
CSO-right 0.3995 ± 0.0881 0.395 ± 0.07125
CSO-left 0.43125 ± 0.398 0.44575 ± 0.08
AL-right 0.398 ± 0.0735 0.38475 ± 0.160
AL-left 0.3875 ± 0.0723 0.3515 ± 0.1135
PL-right 0.649 ± 0.0893 0.59475 ± 0.099
PL-left 0.66775 ± 0.079375 0.604 ± 0.10085
Genu-right 0.378 ± 0.1255 0.3555 ± 0.1219
Genu-left 0.433 ± 0.100 0.425 ± 0.1336
SPL-right 0.61 ± 0.1413 0.629 ± 0.118
SPL-left 0.63675 ± 0.14315 0.67 ± 0.13015
Peduncles-right 0.555 ± 0.126 0.60725 ± 0.149
Peduncles-left 0.512 ± 0.1016 0.53 ± 0.12065
cells met the required standards of the ISCT, the PDT, and
cell surface marker expression and diﬀerential potential was
observed to be lesser than healthy donor BMMSCs. This may
be attributed to the higher age of the patient where cells are
known to have shorter telomere length [23] and lower pro-
liferation potential. These cells also reached senescence in
vitromuchearlier(Passage3)andhenceitwaschallengingto
be able to upscale the cells for transplantation (unpublished
data). The mixed results obtained may be attributed to the
diﬀerences in the cell properties observed.
In view of the preceding results, in this study we wanted
to understand the safety and feasibility of bilateral “allo-
genic” bone-marrow-derived mesenchymal stem cells for
PD. The rationale was to rule out bone marrow aspiration in
the aging population of PD patients and the morbidity asso-
ciatedwithit.Inthecurrentstudy,wehavetransplantedallo-
genic healthy donor mesenchymal cells at passage 2. These
cells are easy to upscale in vitro, maintain diﬀerential poten-
tial and cell surface marker expression. It is believed that
these cells will have potentially higher therapeutic beneﬁts.
Since these cells can be produced in a large scale, cell expan-
sion would also help to make the therapy more aﬀordable.
And bilateral transplantation would prevent any further deg-
eneration on the contralateral side.
After receiving appropriate approvals, the study was con-
ducted in 8 PD patients and 4 PD plus patients. The small
numberwaschosentounderstandthesafetyofinjectingallo-
genic adult bone marrow mesenchymal stem cells into the
subventricular zone of PD patients.
4.1. Our Hypothesis. Parkinson’s disease involves both the
nigral and extranigral systems. As a result, there are motor
complications, associated dementias, multiple system dys-
functioning, and decline in cognitive functions with time.
Most studies have focused on the motor aspects only
which are due to the loss of dopaminergic neurons (DA) in
thesubstantianigra ofthe midbrain. Cell replacementexper-
iments conducted till date are targeted towards the replace-
ment of the DA neurons. The results of fetal mesencepha-
lic transplantation show graft induced dyskinesias due to10 Stem Cells International
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Figure 5: Depicts the balance between degeneration due to illness
andtheneuroregenerativereservepresentinthebrain.Theschema-
ticdiagramillustratesthathigherthedegenerationhighertheillness
and more the regeneration required. Exogenous supply of stem cells
midwaybetweenthesetwostages(i.e.,50%)wouldaidinimproving
the quality of life and reducing the disability due to disease.
inﬂammation around the implants, mixed population of DA
neurons, and inappropriate synaptic contacts [6, 8–10].
T h e r e f o r e ,i no u rs t u d yw eo p t e dt oc h o o s eac e l lt y p e
which would primarily help in neuroprotection of the aﬀec-
ted region irrespective of the cell type, followed by neuroge-
nesis. This is a more global approach to the problem which
would target not only the classical motor symptoms but also
associated memory loss and decline of cognitive functions.
Our primary aim was to forestall the progress of the disease
and secondly help in restoration of neural functions. This is
the ﬁrst paper to demonstrate that bilateral allogenic trans-
plantationofadultbone-marrow-derivedmesenchymalstem
cells is safe and has beneﬁcial neuroprotective and neu-
rorestorative eﬀects in PD patients.
In this context, it is imperative to understand how mes-
enchymal stem cells help in neuroprotection and neurogene-
sis.
It is well established that BMMSCs are capable of releas-
ingcytotrophicmediatorssuchasnervegrowthfactor(NGF)
superfamily-Brain-derived neurotrophic factor (BDNF) and
NGF-3;Glial-derivedneurotrophicfactor(GDNF)andneur-
turin [26]. These neurotrophic factors are essential for
neurogenesis, neuroprotection, neuronal survival and dif-
ferentiation. In PD animal models-mesenchymal stem cells
are known to slow the progress of degeneration, improve
neighbouring neuronal activity, regenerate nerve ﬁbres, and
most signiﬁcantly induce proliferation and diﬀerentiation of
the resident pool of neural stem cells [27].
Data from animal studies also demonstrate that inﬂam-
mation at the SN of the midbrain leads to signiﬁcant loss
of dopaminergic neurons. Also there is a noted increase in
the levels of tumour necrosis factors-α, interleukin 1β and
γ interferon in the SN of PD patients [28]. Mesenchymal
stem cells are known immunomodulatory. In vitro stu-
dies show that they are involved in immunosuppressive acti-
vitiesalthoughthemechanismofactionneedsfurtherclarity.
In autoimmune encephalomyelitis animal models, mes-
enchymal stem cells have demonstrated a reduction in
inﬂammatory inﬁltrates, lesser relapses, and neural insults.
Recent studies are suggesting that NSAIDs are said to have
beneﬁcialeﬀectsinPDpatients.Ananti-inﬂammatorybene-
ﬁcialeﬀectofmesenchymalstemcellsisbeingproposedhere.
The neural stem cells are located in the subventricular
zone of the brain and hence is the most preferred site of
injection in this study although invasive. The exogenous
BMMSCs would help to activate and increase proliferation
of the resident stem cells which has regenerative capacities
(endogenous regeneration). At the same time, SVZ is far
away from the known lesioning targets in the brain.
In this study, we report that there is 22% improvement in
the UPDRS scores of the patients treated. The improvement
was noticed only in the early diseased patients and not in PD
plus. At the end of the study (12 months) it was not required
to increase the medication which is an indicator that disease
progression has been prevented. Further follow-up studies
are on-going. No study till date has reported the ability to
stallprogressionofPDinpatients.ConcurrenttotheUPDRS
scores, there was a sense of subjective well being perceived by
the patient and caregivers in 10 out of 12 patients.
For PD plus, 3 patients have shown slight transient
improvement post stem cell transplantation. In 1 patient
there was no noticeable change. We feel that BM-mesenchy-
mal stem cells should be considered as a treatment of choice
in early-stage PD patients to appreciate maximum beneﬁts.
This is due to the loss of the “neuroregenerative reserve”
present in the brain. It proves the fact that once the disease
has progressed further and involves multiple areas, it is dif-
ﬁcult to stop the process. Also the degeneration is so exten-
sive and rapid that it is beyond the reparative capacity of
the exogenous bone marrow mesenchymal stem cells to help
in neuroprotection and neurogenesis. We also assume that
the degeneration process is slow in the initial phases and
gains momentum with time. PD plus appears to be involving
multiple areas of degeneration de novo and hence none of the
drugs or surgery are useful. Unfortunately cell therapy does
not seem to alter the course. This creates a need for further
studies where we need to consider the option of providing
multiple doses of cells at frequent intervals and/or test the
potential of stem cells derived from a diﬀerent source like
adipose tissue or umbilical cord matrix as these are also
known to possess neuroprotective eﬀects and higher trans-
diﬀerentiation potentials. At baseline and 12 months after
stem cell transplantation, MRI of the brain was performed.
Although there has been improvement in symptoms and no
further progression of the disease, there were no structural
changes observed in the MRI scan. The MR tractography
results show a speciﬁc pattern of recovery. Certain structural
changes were observed in the genu of the corpus callosum
and the left peduncle suggesting that early regeneration of
the tracts probably occurs here. These changes are persistent
throughoutthefollow-upstudyandclinicallycorrelatedwithStem Cells International 11
improvements reported in the patients. Currently we are
continuing the study, with PET scans which will give us valu-
able information on any metabolic and functional changes
happening in the SN region of the midbrain. This would give
us further valuable clues in to the mechanism of regenera-
tion in the human PD-aﬀected brain.
Thus, to summarize, BM-mesenchymal stem cells have a
three pronged therapeutic approaches in neurodegenerative
diseases such as PD: neurogenesis, neuroprotection and neu-
ral plasticity. Also, it is essential to expose the degenerating
braintotheexogenousstimulusofstemcells,whiletheinsitu
neuroregenerative reservoir of stem cells is present that is, in
the early part of the disease.
5. Conclusion
This is the ﬁrst paper to demonstrate that bilateral allogenic
transplantationofadultbone-marrow-derivedmesenchymal
stem cells is safe and has beneﬁcial neuroprotective and neu-
rorestorative eﬀects.
The study establishes the safety of adult bone-marrow-
derived mesenchymal stem cell transplantation bilaterally
into the subventricular zone of the human brain using burr
hole surgery. There are improvements in the UPDRS scores
of the PD patients, reported subjective well being and no
increase in medications during the follow-up period. It is
to be noted that no improvements were observed in the PD
plus patients. This strengthens the fact that stem cell trans-
plantation in the early stages of PD has the potential to pre-
vent further progress of the disease. Results from this study
suggest that allogenic BM-mesenchymal stem cells may be
used as a disease modifying therapeutic strategy in treating
PD. Unlike the known indications for surgical intervention,
werecommendinterventionintheearlypartofthediseaseto
reap the best beneﬁts. However, further long-term follow-up
studies need to be carried out to understand the long term
safety and sustainability of the beneﬁt. Currently studies are
going on to elucidate the mechanism of action of these cells
in neuroprotection and neurogenesis in PD-aﬀected human
brain.
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